SUMMARY OF INTERVIEW

Exhibits and/or Demonstrations

none

Identification of Claims Discussed

Claim 6

Identification of Prior Art Discussed

Sirois, G. (US 2003/0186920)

Peichev, et al. (IDS 7/22/04)

Majka, et al. (PTO Form 892, 12/19/05)

Schmeisser, et al. (Cardiovascular Research, 2001, 49: 671-680)

Proposed Amendments

A proposed amendment to claim 6 was faxed to the Examiner in advance.

Principal Arguments and Other Matters

Applicants' representative argued that the cited references do not teach a role for prominin-1 (AC133) in angiogenesis and, even if that argument is not accepted, none of the references teach a specific role for prominin-1 in pathological angiogenesis. In the proposed amendment, claim 6 has been amended to recite "without affecting normal vascular development" consistent with the second argument.

Peichev, et al. teach CD34+ cells which may play a role in angiogenesis. Although these cells express AC133, Peichev, et al. do not provide any teaching on a role for AC133 directly in angiogenesis. In fact, Peichev, et al. teach that the role of AC133 is unknown.

Majka, et al. use antisense oligonucleotides against AC133 but cannot determine a biological function.

Sirois teach VEGF and that is involved in both normal and pathophysiological angiogenesis.

Schmeisser, et al. primarily refer to Peichev, et al. for teachings on AC133.

Results of Interview

Examiner Chong will consider amendment and arguments upon submission.